Bayer Foundation presents Science Awards
This year the Bayer Foundation is presenting their renowned Hansen Family Award to Professor Claudia Höbartner. The Hansen Family Award is presented alternating with the Otto Bayer Award every second year.…
Read MoreBayer Foundation presents Science Awards
Bayer collaboration with Microsoft connects farm data to address lack of data interoperability in agriculture
Bayer today announced at Agritechnica, the world’s leading trade fair for agricultural machinery, an update on the strategic collaboration with Microsoft: New data connectors allow secure, compliant exchange of farm…
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today presented first-in-human data from a Phase 1 trial investigating AB-1002…
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark Novo Nordisk today announced plans to invest more than 42 billion Danish kroner…
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys®…
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide…
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial Positive high-level results from the EMERALD-1 Phase III trial showed…
Bayer and Recursion focus research collaboration on Oncology
Bayer and Recursion focus research collaboration on Oncology Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have…
Takeda’s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura.
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Takeda (TSE:4502/NYSE:TAK) today…
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic Prostate Cancer AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients,…
New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease
New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics,…
BioPhy Launches Breakthrough AI Platform to Accelerate the Trillion Dollar Drug Development Market
BioPhy Launches Breakthrough AI Platform to Accelerate the Trillion Dollar Drug Development Market BioPhy today launched its AI operating system that radically accelerates the identification and development of the most…